KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lam Research (LRCX) Cash & Equivalents (2016 - 2026)

Lam Research has reported Cash & Equivalents over the past 18 years, most recently at $4.8 billion for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 12.84% year-over-year to $4.8 billion; the TTM value through Mar 2026 reached $4.8 billion, down 12.84%, while the annual FY2025 figure was $6.4 billion, 9.28% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $4.8 billion at Lam Research, down from $6.2 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $6.7 billion in Q3 2025 and troughed at $3.5 billion in Q2 2022.
  • A 5-year average of $5.3 billion and a median of $5.5 billion in 2025 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: fell 20.29% in 2022 and later soared 51.53% in 2023.
  • Year by year, Cash & Equivalents stood at $4.5 billion in 2022, then rose by 25.39% to $5.6 billion in 2023, then increased by 0.75% to $5.7 billion in 2024, then rose by 9.09% to $6.2 billion in 2025, then dropped by 23.13% to $4.8 billion in 2026.
  • Business Quant data shows Cash & Equivalents for LRCX at $4.8 billion in Q1 2026, $6.2 billion in Q4 2025, and $6.7 billion in Q3 2025.